Fifteen years follow up after studying 223 patients with localized prostate cancer showed that radioactive seed implants are a highly effective treatment in combination with conventional external beam radiation.

Seed implants, also called brachytherapy, are small radioactive pellets about the size of a grain of rice. The pellets are implanted into the prostate; they deliver radiation to the prostate cancer from the inside.

Most good-prognosis patients who choose seed implants do not receive other treatments. Patients with more aggressive tumors may get seed implants plus external beam radiation.

Three out of four patients in the study remained disease free at least 15 years after treatment ended. It is not clear from the study if the patients would have fared equally well with either the seed implants or external-bean radiation therapy alone, however they are confident the combined therapy is very effective in treating prostate cancer.

Testicular cancer, cancer in one or both of the testicles, usually occurs in young men and will strike about 8,250 of these men this year. About 370 men will die.

A man's lifetime risk of developing this cancer -- that typically shows up in only one testicle -- is 1 in 300, securing it as one of the less common cancers in the United States. The chances of dying from testicular cancer are 1 in 5,000, making it one of the most curable forms of cancer. Yet it is still the most common form of cancer in men ages 15-34. It is also a cancer commonly characterized by denial and embarrassment. As a result, it is one of the least mentioned cancers.

On January 14, 2005, my sister drove me to the hospital for my port placement -- a minor surgical procedure to implant an Infuse-a-Port® underneath the skin on my collarbone. My port -- used steadily ever since that January day for the infusion of breast cancer chemotherapy drugs -- is about to be removed.

Tomorrow -- September 15, 2006 -- my sister will drive me to the same hospital where another minor surgery will result in the removal of this same port and its accompanying parts. I will come home with a scar that will mark the spot symbolic of my cancer travels. Along with my healed lumpectomy incisions and my head full of new hair, this scar will remind me of where I've been and will not ever let me lose sight of where I'm going -- full steam ahead into a life I am blessed to have in front of me. A life that was never promised to me for any specific amount of time. A life I am going to wrap my arms around -- for every second, every minute, every breath I am lucky enough to take.

I can't decide what to do about my port now that my breast cancer treatment is over. It's been an on-going internal battle. I don't know whether I should leave it in place -- tunneled underneath the skin on my collarbone where it is available and accessible should I ever need further infusions of cancer-fighting drugs -- or whether I should have it removed since there is no real purpose for it right now. There is the issue of superstition and safety -- leaving it right where it is allows for easy use if cancer returns and prevents another surgery to implant a new one. But there is also the issue of moving on -- and removing it because I don't need it, because I may never need it. One doctor told me recently that it should come out because if it remains in my body, I risk infection. And anything foreign in my body for an extended period of time is not completely safe. But a cancer survivor told me that she had hers removed immediately after treatment and had to get a new one because her cancer recurred three months later.

I am accustomed to wrestling matches like this one -- like my stand-off between treatment with Taxol or without Taxol, between anti-depressant or no anti-depressant, between vegan diets and traditional diets. Sometimes I can make a good call. Sometimes I just can't decide. Like right now.

Horizon Blue Cross and Blue Shield of New Jersey announced plans to launch a test program where they will be implanting an ID microchip in people who suffer from chronic diseases. The radio frequency identification device (RFID) microchip will include family contact information and medical history. The purpose is to give emergency room medical staff the ability to access a patient's information if they are brought to the emergency room and are unable to speak on their own.

According to the test program team, Horizon will start sending letters to patients with chronic diseases explaining the new program and inviting them to participate. The program will be cost-free and voluntary for those who wish to participate.

RFID implanted microchips in surgical sponges is one thing -- in people? I don't know.

I am taking an informal poll. Would you consent to having a microchip implanted in your right arm for the purpose of information retrieval?

In woman with fake boobs has real health worries, Busty and bothered wrote to women's medical health expert Dr. Judith Reichman asking if her breast implants will rupture during a mammogram or if there is a possibility that the implants will obscure signs of breast cancer. Dr. Reichman, who is NBC Today show's medical contributor on women's health, responded that both are valid concerns for the over four million women who have had breast augmentation. According the doctor, there were only 41 cases of implant ruptures during mammography reported to the U.S. Food and Drug Administration between June 1992 and October 2002.

As to breast implants obscuring mammography readings, implants can cause a 15 to 50 percent decrease in the mammographically visualized breast tissue and several studies have reported false negative mammograms -- those that missed the cancer -- in 12 to 67 percent of women with breast implants. So, it's a bit of good news and bad news but women with breast implants should not put off having mammograms because of fear that the implants will be damaged or that there is no point in having a mammogram because there is a possibility the implants will obscure the early signs of breast cancer.

Purdue University engineers are creating a wireless device the size of a grain of rice that will then be implanted in tumors for the delivery and tracking of cancer-fighting radiation. The dime-sized prototype, as shown in the photo, has been successfully tested and the researchers believe the smaller rice-sized version will be completed this year. The device will be activated with electrical coils placed next to the body.

According to Purdue engineer Babak Ziaie, "Currently, there is no way of knowing the exact dose of radiation received by a tumor. Because most organs shift inside the body depending on whether a patient is sitting or lying down, for example, the tumor also shifts. This technology will allow doctors to pinpoint the exact position of the tumor to more effectively administer radiation treatments."

"This will be a radiation dosimeter plus a tracking device in the same capsule." Very cool. Perhaps one day they can stop the dynamite-fishing approach of current cancer treatment where healthy cells and tissue are destroyed in an attempt to destroy cancer cells and tumors. Then it will be welcome to the 21st century of medicine.

Photo credit: David Umberger. Purdue News Service. Babak Ziaie shows the prototype wireless device he has developed with doctoral student Chulwoo Son at the university's Birck Nanotechnology Center.

At the University of Bath, researchers believe they have found a new method of delivering chemotherapy to cancer patients without patients having to endure the traditional chemotherapy side effects of  hair loss and nausea. In development stages now, the method involves using tiny fibers and beads soaked in a chemotherapy drug, which are then implanted into the cancerous area of the patient’s body. As any chemotherapy patient knows, chemotherapy drugs are currently administered by an IV drip of toxic chemicals directly into the veins.

The benefit of this new targeted method of chemotherapy delivery will mean lower doses of chemotherapy drugs will be needed, and chemotherapy drugs will not circulate throughout the entire body, damaging healthy cells in order to destroy cancerous cells.

Known as Fibrasorb, the method was developed over the past few years, and has successfully gone through preliminary laboratory trials. The first clinical trials on volunteer patients with ovarian cancer in Avon, Somerset and Wiltshire could begin in the next few years and, if successful, the therapy would then be introduced into wider use.